Oct 5 2013
Capital Pro-Égaux Inc. (the "Company") (NEX: CPE.H) announces that its wholly owned subsidiary, Technique d'usinage Sinlab Inc. ("Sinlab"), has entered into a settlement agreement with Nobel Biocare AB; Nobel Biocare Italiana S.r.l.; Nobel Biocare Holding AG; Nobel Biocare Deutschland GmbH; Nobel Biocare Canada, Inc., a Canadian federal corporation; Biocad Médical Inc., a Quebec provincial corporation; Nobel Biocare USA, LLC, a Delaware limited liability company; and Nobel Biocare Procera, LLC, a Delaware limited liability company; (collectively "Nobel Entities") pursuant to which it settled civil actions in the United States, Canada, Italy and Germany involving the Nobel Entities and Sinblab. As part of the agreement, Sinlab granted Nobel a license in and to all of its patents, including patents relating to its Technobar and Technoguide technologies, under terms undisclosed for confidentiality reasons.
Caution regarding forward-looking statements
This news release contains certain forward-looking statements regarding the Company's expectation of future events, including potential claims and legal proceedings. Such expectations are based on certain assumptions based on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could lead actual results to differ include, amongst others, factors that may impact claims and legal proceedings, such as interpretation of factual matters, time and money involved in undertaking legal proceedings, uncertainty as to the final result and other risks. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by securities laws.
Source: Pro-Égaux Inc.